Related references
Note: Only part of the references are listed.An update of current treatments for adult acute myeloid leukemia
Herve Dombret et al.
BLOOD (2016)
Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS
Raya Mawad et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells
E. Chang et al.
LEUKEMIA (2016)
Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
G. Garcia-Manero et al.
LEUKEMIA (2016)
Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia
C. Mueller-Tidow et al.
LEUKEMIA (2016)
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome
Rupa Narayan et al.
LEUKEMIA & LYMPHOMA (2016)
Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial
Charles Craddock et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses
Marjan Cruijsen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts
Sumithira Vasu et al.
BLOOD (2016)
Greater Than the Sum of Parts: Complexity of the Dynamic Epigenome
Alexey A. Soshnev et al.
MOLECULAR CELL (2016)
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia
Sheng Li et al.
NATURE MEDICINE (2016)
Epigenetic Modulators and the New Immunotherapies
Anthony E. Dear
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts
Tapan M. Kadia et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia
Ashkan Emadi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome
Paolo Strati et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG)
Heiko Becker et al.
ANNALS OF HEMATOLOGY (2015)
Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Iskra Pusic et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation
Elmina Mammadova-Bach et al.
BLOOD (2015)
Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification
Paolo Strati et al.
BLOOD (2015)
Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia
Andrew Wei et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia
Monica R. Muppidi et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
A Phase I Study of Midostaurin and Azacitidine in Relapsed and Elderly AML Patients
Brenda W. Cooper et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
Jean-Pierre J. Issa et al.
LANCET ONCOLOGY (2015)
Azacitidine for the treatment of relapsed and refractory AML in older patients
Raphael Itzykson et al.
LEUKEMIA RESEARCH (2015)
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction
F. Ramos et al.
LEUKEMIA RESEARCH (2015)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
Andreas D. Orskov et al.
ONCOTARGET (2015)
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
Hartmut Doehner et al.
BLOOD (2014)
Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study
Roland B. Walter et al.
HAEMATOLOGICA (2014)
Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
Thomas Prebet et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H. Yang et al.
LEUKEMIA (2014)
The mechanistic role of DNA methylation in myeloid leukemogenesis
J. Jasielec et al.
LEUKEMIA (2014)
Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents
Courtney D. DiNardo et al.
LEUKEMIA & LYMPHOMA (2014)
Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts
Pragya Srivastava et al.
LEUKEMIA RESEARCH (2014)
Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine
Cecile Bally et al.
LEUKEMIA RESEARCH (2014)
A vaccine targeting mutant IDH1 induces antitumour immunity
Theresa Schumacher et al.
NATURE (2014)
Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome
P. Tan et al.
BLOOD CANCER JOURNAL (2014)
5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy
Sarah Ivanoff et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia
Omar Abdel-Wahab et al.
BLOOD (2013)
A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia
Sucha Nand et al.
BLOOD (2013)
Genomic impact of transient low-dose decitabine treatment on primary AML cells
Jeffery M. Klco et al.
BLOOD (2013)
A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML
G. Ramsingh et al.
LEUKEMIA (2013)
Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia
A. Mims et al.
LEUKEMIA (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Preclinical and Phase I Results of Decitabine in Combination with Midostaurin (PKC412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia
Casey B. Williams et al.
PHARMACOTHERAPY (2013)
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia
Alfonso Quintas-Cardama et al.
BLOOD (2012)
Azacitidine for the treatment of patients with acute myeloid leukemia
Luca Maurillo et al.
CANCER (2012)
A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy
Michael Luebbert et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia
D. A. Pollyea et al.
LEUKEMIA (2012)
DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
K. H. Metzeler et al.
LEUKEMIA (2012)
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Jay P. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
R. Itzykson et al.
LEUKEMIA (2011)
Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)
Sylvain Thepot et al.
BLOOD (2010)
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Patrick S. Ward et al.
CANCER CELL (2010)
DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia
Maria E. Figueroa et al.
CANCER CELL (2010)
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Pierre Fenaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia
Amanda F. Cashen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells
Maika Almstedt et al.
LEUKEMIA RESEARCH (2010)
DNMT3A Mutations in Acute Myeloid Leukemia.
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
William Blum et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome
Emmanuel Raffoux et al.
ONCOTARGET (2010)
Mutation in TET2 in Myeloid Cancers
Francois Delhommeau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
Elaine R. Mardis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial
Sucha Nand et al.
LEUKEMIA & LYMPHOMA (2008)
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome
Andres O. Soriano et al.
BLOOD (2007)
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Hagop Kantarjian et al.
BLOOD (2007)
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B
Lewis R. Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias
M de Lima et al.
CANCER (2003)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine
M Lübbert et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)